

DAFTAR PUSTAKA

- Ali, S., & Coombes, R.C. (2002). Endocrine-responsive Breast Cancer and Strategies for Combating Resistance. *Nature Reviews Cancer*, 2(2), pp. 101–112. <https://doi.org/10.1038/nrc721>
- Athina, M., Martha, Z., Evi, SL. (2015). MicroRNA signatures as clinical biomarkers in lung cancer. *Current Biomarker Findings*, 5, pp. 35-45. <https://www.dovepress.com/micrna-signatures-as-clinical-biomarkers-in-lung-cancer-peer-reviewed-fulltext-article-CBF>
- American Cancer Society. (2014). Cancer Facts & Figures 2014. [ebook] Cancer.org. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2014/cancer-facts-and-figures-2014.pdf> [Accessed 23 Aug. 2018].
- American Cancer Society. (2018). *Non-Small Cell Lung Cancer Survival Rates, by Stage*. [online] Cancer.org. Available at: <http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates.html> [Accessed 23 Aug. 2018].
- Amit, I., Wides, R., and Yarden, Y. (2007). Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. *Mol. Syst. Biol*, 3, p. 151. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174628/>
- Ana, LT., Monica, G., Rui, M. (2012). EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. *Frontiers in Genetics*, 3, p. 286. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516830/>
- Apama, S., Suresh, M., C, Babu., Govind, K., Babu., Suresh, T.M. (2015). Hyperleukocytosis, an unusual paraneoplastic manifestation of lung cancer: Case report and review of literature. *J Can Res Ther*, 11, p. 699. <https://www.cancerjournal.net/article.asp?issn=09>.
- Ardizzoni, A., Cafferata, M.A., Tiseo, M., Filiberti, R., Marroni P., et al. (2006) Decline in Serum Carcinoembryonic Antigen and Cytokeratin 19 Fragment During Chemotherapy Predicts Objective Response and Survival in Patients With Advanced Nonsmall Cell Lung Cancer. *Cancer*, 107, pp. 2842-9. <https://www.ncbi.nlm.nih.gov/pubmed/17103443>
- Ariazi, E. A., Ariazi, J. L., Cordera, F., & Jordan, V. C. (2006). Estrogen receptors as therapeutic targets in breast cancer. *Current Topics in Medicinal Chemistry*, 6(3), pp. 181–202. <https://doi.org/10.2174/156802606776173483>
- Ashokakumar, M.P., David, G., Davila, M.D., Steve, G. (1993). Paraneoplastic Syndromes Associated With Lung Cancer. *Mayo Clin Pro*, 68, pp. 278-287.

- Bommer, G.T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., et al. (2007). p53-mediated activation of miRNA-34 candidate tumor-suppressor genes *Current Biology*, 17(15), pp.1298–1307.
<https://doi.org/10.1016/j.cub.2007.06.068>
- Bos, M., Mendelsohn, J., Kim, Y. M., Albanell, J., Fry, D.W., and Baselga, J. (1997). PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number dependent manner. *Clin. Cancer Res*, 3, pp. 2099–2106.
<https://pubmed.ncbi.nlm.nih.gov/9815602/>
- Brighenti, M. (2015). MicroRNA and MET in lung cancer. *Annals of Translational Medicine*, [online] 3(5), p. 68. Available at:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402600/> [Accessed 07 July 2018]
- Calin, G.A., Croce, C.M. (2006) Micro-RNA Signatures in Human Cancers. *Nat Rev Cancer*, 6(11), pp. 857-866. <https://www.nature.com/articles/nrc1997>
- Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proceedings of the National Academy of Sciences of the United States of America*, 101(9), pp. 2999–3004. <https://doi.org/10.1073/pnas.0307323101>
- Cappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., et al. (2009). Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients. *Journal of Clinical Oncology*, 27(10), pp. 1667–1674.
<https://doi.org/10.1200/JCO.2008.19.1635>
- Cécile, O., Marie, P.P., Marius, I., Pascal, B., Bernard, M., Paul, H., et al. (2009). MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets. *Current Medicinal Chemistry*, 16, pp. 1047-1061.
<https://www.eurekaselect.com/node/68770>
- Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., et al. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Molecular Cell*, 26(5), pp. 745–752. <https://doi.org/10.1016/j.molcel.2007.05.010>
- Changming, Z., Shaoshan, L., Shuiqin, C., Wei, L., Chunxia, Z., et al. (2018). Urinary miR-196a predicts disease progression in patients with chronic kidney disease. *Journal of Translation Medecine*, 16, p. 91.
<https://link.springer.com/article/10.1186/s12967-018-14>
- Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. *Molecular Cell*, 17(3), pp. 393-403. <https://doi.org/10.1016/j.molcel.2004.12.030>

- Cheng, E. H., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., et al. (2001). BCL-2, BCL-X_L sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. *Molecular Cell*, 8(3), pp. 705-711. [https://doi.org/10.1016/S1097-2765\(01\)00320-3](https://doi.org/10.1016/S1097-2765(01)00320-3)
- Chinmoy, KB., Subhashis, D., Ashis, M. (2011). Hyponatremia of non-small cell lung cancer: Indian experiance. *Indian J Med Paediatr Oncol*, 32(3), pp. 139-142. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342719/>
- Chipuk, J. E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D.D., & Green, D.R. (2005). PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. *Science*, 309(5471), pp. 1732-1735. <https://doi.org/10.1126/science.1114297>
- Cohen, M. H., Johnson, J. R., Chen, Y. F., Sridhara, R., & Pazdur, R. (2005). FDA drug approval summary: erlotinib (Tarceva) tablets. *The Oncologist*. 10(7), pp. 461-466. <https://doi.org/10.1634/theoncologist.10-7-461>
- Comoglio, P. M., & Trusolino, L. (2002). Series Introduction: Invasive growth: from development to metastasis. *The Journal of Clinical Investigation*, 109(7), pp. 857–862. <https://doi.org/10.1172/JCI15392>
- Corso, S., Migliore, C., Ghiso, E., De Rosa, G., Comoglio, P. M., & Giordano, S. (2008). Silencing the MET oncogene leads to regression of experimental tumors and metastases. *Oncogene*, 27(5), pp. 684–693. <https://doi.org/10.1038/sj.onc.1210697>
- Costanzo, R., Montanino, A., Di Maio, M, Piccirillo, M. C., Sandomenico, C., Giordano, P., et al. (2013). Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. *Expert Review of Anticancer Therapy*, 13(10), pp. 1207-1218. <https://doi.org/10.1586/14737140.2013.845092>
- Davis-Dusenbery, B. N., & Hata, A. (2010). Mechanisms of control of microRNA biogenesis. *Journal of Biochemistry*, 148(4), pp. 381–392. <https://doi.org/10.1093/jb/mvq096>
- De Muga, S., Hernandez, S., Agell, L., Salido, M., Juanpere, N., Lorenzo, M., et al. (2010). Molecular alterations of EGFR and PTEN in prostate cancer: association with high grade and advanced stage carcinomas. *Mod. Pathol.* 23, pp. 703–712. <https://pubmed.ncbi.nlm.nih.gov/20208477/>
- Detassis, S., Grasso, M., Del Vescovo, V., & Denti, M. A. (2017). microRNAs Make the Call in Cancer Personalized Medicine. *Frontiers in Cell and Developmental Biology*, 5, p. 86. <https://doi.org/10.3389/fcell.2017.00086>
- Dilaver, T. (2018). Paraneoplastic Syndromes in Lung Cancer. *Lung Cancer - Strategies for Diagnosis and Treatment*, 2 , pp. 23-42. <http://dx.doi.org/10.5772/intechopen.79127>

- Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., McCormack, R., Webster, A., et al. (2014). First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. *British Journal of Cancer*, 110(1), pp. 55–62. <https://doi.org/10.1038/bjc.2013.721>
- Daugaard, I., Knudsen, A., Kjedsen, TE., Hager, H., Hansen, LL., et al. (2017). The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma. *Exp Mol Pathol*, 102(3), pp. 484-491. <https://www.ncbi.nlm.nih.gov/pubmed/28512015>.
- Dungo, R. T. & Keating, G. M. (2013). Afatinib: first global approval. *Drugs*, 73(13), pp. 1503–1515. <https://doi.org/10.1007/s40265-013-0111-6>
- Ettinger, D. S. (2012). Ten years of progress in non–small cell lung cancer. *Journal of the National Comprehensive Cancer Network*, 10(3), pp. 292–295. <https://doi.org/10.6004/jnccn.2012.0029>
- Fatiha, T., Valerie, M., Eleonore, M., Mohamedm seif, D., Loic, L., et al. (2014). Possible involvement of microRNAs in vascular damae in experimental chroni kidney disease. *Biochimica et Biophysica Acta(BBA)*, 1842(1), pp. 88-98. <https://www.sciencedirect.com/science/article/pii/S0925>.
- Feng, Y., Thiagarajan, P. S., & Ma, P. C. (2012). MET signaling: novel targeted inhibition and its clinical development in lung cancer. *Journal of Thoracic Oncology*, 7(2), pp. 459-467. <https://doi.org/10.1097/JTO.0b013e3182417e44>
- Fernando, U., Asha, K., Kiran, B., Sachin, S., Suhny, A., Prabhakar, R. (2017). Revisions to the tumor, node, metastasis staging of lung cancer (8th edition): rationale, radiologic findings and clinical implication. *World J Radiol*, 9(6), pp. 269-279. <https://www.ncbi.nlm.nih.gov/pmc/article/PMC54916>
- Forde, P. M., & Ettinger, D. S. (2013). Targeted therapy for non-small-cell lung cancer: past, present and future. *Expert Review of Anticancer Therapy*, 13(6), pp. 745–758. <https://doi.org/10.1586/era.13.47>
- Frank, C., Detterbeck,., (2017). The eighth edition TNM stage classification for lung cancer: what does it mean on main street. *J Thorac Cardiovasc Surg*, 155, pp. 356-9. [https://www.jtcvs.org/article/S0022-5223\(17\)321](https://www.jtcvs.org/article/S0022-5223(17)321).
- Fry, D. W., Kraker, A. J., Mc Michael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., et al. (1994). A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. *Science*, 265, pp. 1093–1095. <https://pubmed.ncbi.nlm.nih.gov/8066447/>
- Fukuoka, M., Wu, Y. L., Thongprasert, S., Sunpaweravong, P., Leong, S. S., Sriuranpong, V., et al. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). *Journal of clinical oncology*, 29(21), pp. 2866–2874. <https://doi.org/10.1200/JCO.2010.33.4235>

- Garofalo, M., Quintavalle, C., Di Leva, G., Zanca, C., Romano, G., Taccioli, C., et al. (2008). MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. *Oncogene*, 27(27), pp. 3845–3855. <https://doi.org/10.1038/onc.2008.6>
- Garofalo, M., Romano, G., Di Leva, G., Nuovo, G., Jeon, Y.-J., Nganheu, A., et al. (2012). EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. *Nature Medicine*, 18(1), pp.74–82. <https://doi.org/10.1038/nm.2577>
- Gift, A.G., Jablonski, A., Stommel, M., & Given, C. W. (2004). Symptom clusters in elderly patients with lung cancer. *Oncology Nursing Forum*, [online] 31(2), pp. 202- 212. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15017438> [Accessed 23 Aug. 2018]
- Ghaleb, E., Ali, M.A., Eman, B. (2014) Cancerassociated thrombosis: an overview. *Clin Med Insights Oncol*, 8, pp. 129–37. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259501/>
- Gillies, J. K., & Lorimer, I. A. (2007). Regulation of p27^{Kip1} by miRNA 221/222 in glioblastoma. *Cell Cycle*, 6(16), pp. 2005-2009. <https://doi.org/10.4161/cc.6.16.4526>
- Graham, JC., Paul, SS., Gregory, YH., Sean, TK. (2002). The hypercoagulable state of malignancy: Pathogenesis and current debate. *Neoplasia*, 4(6), pp. 465-473. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC15503>
- Guo, A., Villén, J., Kornhauser, J., Lee, K. A., Stokes, M. P., Rikova, K., et al. (2008). Signaling networks assembled by oncogenic EGFR and c-Met. *Proceedings of the National Academy of Sciences of the United States of America*, 105(2), pp. 692–697. <https://doi.org/10.1073/pnas.0707270105>
- Guz, M., Rivero-Müller, A., Okoń, E., Stenzel-Bembenek, A., Polberg, K., Słomka, M., & Stepulak, A. (2014). MicroRNAs-Role in Lung Cancer. *Disease Markers*, p. 218169. <https://doi.org/10.1155/2014/218169>
- Hackshaw, A. K., Law, M. R., & Wald, N. J. (1997). The accumulated evidence on lung cancer and environmental tobacco smoke. *BMJ: British Medical Journal*, 315(7114), pp.980–988. <https://doi.org/10.1136/bmj.315.7114.980>
- Hamada, N., Fujita, Y., Kojima, T., Kitamoto, A., Akao, Y., Nozawa, Y., et al. (2012). MicroRNA expression profiling of NGF-treated PC12 cells revealed a critical role for miR-221 in neuronal differentiation. *Neurochem. Int.* 60, pp. 743–750. <https://pubmed.ncbi.nlm.nih.gov/22465943/>
- Han, F., He, J., Li, F., Yang, J., Wei, J., Cho, W. C., et al. (2015). Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer. *BioMed Research International*, p. 672759. <https://doi.org/10.1155/2015/672759>

- He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., et al. (2007). A microRNA component of the p53 tumour suppressor network. *Nature*, 447(7148), pp.1130–1134. <https://doi.org/10.1038/nature05939>
- Hermeking, H. (2007). p53 enters the microRNA world. *Cancer cell*, 12(5), pp. 414-418. <https://doi.org/10.1016/j.ccr.2007.10.028>
- Hermeking, H. (2010). The miR-34 family in cancer and apoptosis. *Cell death and differentiation*, 17(2), pp. 193–199. <https://doi.org/10.1038/cdd.2009.56>
- Iorio, M.V. Croce, C.M. (2012) “Micro-RNA Involvement in Human Cancer”. *Carcinogenesis*, 33, pp. 1126-1133.
- Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., et al. (2009). First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. *Journal of Clinical Oncology*, 27(9), pp. 1394-1400. <https://doi.org/10.1200/JCO.2008.18.7658>
- International Agency for Research of Cancer. (2018). GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. [online] Globocan.iarc.fr. Available at: https://globocan.iarc.fr/Pages/fact_sheets_population.aspx?%20country=360. [Accessed 23 Aug. 2018]
- Johnson, D. H., Schiller, J. H., & Bunn, J. P. (2014). Recent clinical advances in lung cancer management. *Journal of clinical oncology*, 32(10), pp. 973–982. <https://doi.org/10.1200/JCO.2013.53.1228>
- Jorge, JC., Marc, V., Eric, J. (2012). Diagnosis and management of hyponatremia in cancer patients. *Oncologist*, 17(6), pp. 756-765. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380874/>
- Kai-ping, M., Wei-na, Z., Xiao-min, L., Yu-rong, M. (2014). MicroRNA-222 (2014). Expression and its prognostic potensial in non-small cell lung cancer. *Scientificaorldjournal*, 908326. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009118>.
- Kasuga, L., Makino, S., Kiyokawa, H., Katoh, H., Ebihara, Y., Ohyashiki, K. (2001). Tumor -related leukocytosis in linked with poor prognosis in patients with lung carcinoma. *Cancer*, 92(9), pp. 2399-405. <https://www.ncbi.nlm.nih.gov/pubmed/11745296>.
- Ke Zhao, Jing C., Baojun, C., Qi-Liu., Di-Xu., Yongjian, Z. (2017). Circulating microRNA-34 family low expression correlates with poor prognosis in patients with n0n-small cell lung cancer. *J Thorac Dis*, 9(10), pp. 3735-3746. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723759/>

- Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K., Murgo, A., Justice, R., et al. (2014). U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations. *The Oncologist*, 19(7), pp. 774–779. <https://doi.org/10.1634/theoncologist.2014-0089>
- Kim, N. H., Kim, H. S., Li, X.-Y., Lee, I., Choi, H.-S., Kang, S. E., et al. (2011). A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. *The Journal of Cell Biology*, 195(3), pp. 417–433. <https://doi.org/10.1083/jcb.201103097>
- Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004). Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer research*, 64(24), pp. 8919–8923. <https://doi.org/10.1158/0008-5472.CAN-04-2818>
- Kosasih, A. S., Setiawan, L., Hartini, S., Kresno, S. B., & Indraini. (2011) Immunophenotyping in the diagnosis and Classification of Acute Leukemia: “Dharmais” Cancer Hospital Experience. *Indonesian Journal of Cancer*, [online] 5(1), pp. 3–8. Available at: <http://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/84> [Accessed 23 Aug. 2018]
- Krishnaswamy, S., Kanteti, R., Duke-Cohan, J. S., Loganathan, S., Liu, W., Ma, P. C., et al. (2009). Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer. *Clinical Cancer Research*, 15(18), pp. 5714–5723. <https://doi.org/10.1158/1078-0432.CCR-09-0070>
- Kwak, E. L., Jankowski, J., Thayer, S. P., Lauwers, G. Y., Brannigan, B.W., Harris, P. L., et al. (2006). Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. *Clin. Cancer Res*, 12, pp. 4283–4287.
- Kwan, Y.W., Li, Y., Chor, S.C. (2011). DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. *Epigenomics*, 3(1), pp. 83–92. <https://www.ncbi.nlm.nih.gov/pubmed/22126155>
- Landi MT, Zhao Y, Rotunno M, et al. (2010). MicroRNA expression differentiates histology and predicts survival of lung cancer. *Clin Cancer Res*, 16, pp. 430–441. <https://www.ncbi.nlm.nih.gov/pubmed/20068076> [PubMed: 20068076]
- Langer, C. J. (2013). Epidermal growth factor receptor inhibition in mutation-positive non–small-cell lung cancer: is afatinib better or simply newer?. *Journal of Clinical Oncology*, 31(27), pp. 3303–3306. <https://doi.org/10.1200/JCO.2013.49.8782>
- Lawrence, R. E., & Salgia, R. (2010). MET molecular mechanisms and therapies in lung cancer. *Cell Adhesion & Migration*, 4(1), pp. 146–152. <https://doi.org/10.4161/cam.4.1.10973>

- Lee, J., Jang, K.T., Ki, C.S., Lim, T., Park, Y.S., Lim, H.Y., et al. (2007). Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. *Cancer*, 109, pp. 1561–1569.
<https://www.ncbi.nlm.nih.gov/pubmed/17354229>
- Lee, J.W., Soung, Y.H., Kim, S.Y., Nam, H. K., Park, W.S., Nam, S.W., et al. (2005). Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. *Clin. Cancer Res*, 11, pp. 2879–2882.
<https://www.ncbi.nlm.nih.gov/pubmed/15837736>
- Lin, P.-Y., Yu, S.-L., Yang, P.-C. (2010). MicroRNA in lung cancer. *British Journal of Cancer*, 103(8), pp. 1144–1148.
<https://doi.org/10.1038/sj.bjc.6605901>
- Lin, Y., Wang, X., & Jin, H. (2014). EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. *American Journal of Cancer Research*, [online] 4(5), pp. 411–435. Available at:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163608/> [Accessed 04 July 2018].
- Lizé, M., Klimke, A., & Dobbelstein, M. (2011). MicroRNA-449 in cell fate determination. *Cell cycle*, 10(17), pp. 2874–2882.
<https://doi.org/10.4161/cc.10.17.17181>
- Lodes, M. J., Caraballo, M., Suci, D., Munro, S., Kumar, A., & Anderson, B. (2009). Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray. *PLoS ONE*, 4(7), p.e6229.
<https://doi.org/10.1371/journal.pone.0006229>
- Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., et al. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. *Cell cycle*, 7(16), pp. 2591–2600.
<https://doi.org/10.4161/cc.7.16.6533>
- Lovly, C. M., Horn, L., & Pao, W. (2018). Molecular Profiling of Lung Cancer. *My Cancer Genome*. [online] Mycancergenome.org. Available at:
<https://www.mycancergenome.org/content/disease/lung-cancer/> [Accessed 23 Aug. 2018].
- Luize, G.L., Robson, Q.M. (2013). Activation of blood coagulation in cancer: implications for tumour progression. *Biosci Rep*, 9(4), pp.33(5).
<https://www.ncbi.nlm.nih.gov/pubmed/23889169>
- Ma, L., & Weinberg, R. A. (2008). Micromanagers of malignancy: role of microRNAs in regulating metastasis. *Trends in genetics*, 24(9), pp. 448–456.
<https://doi.org/10.1016/j.tig.2008.06.004>
- Maroof, H., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2014). MicroRNA-34 family, mechanisms of action in cancer: a review. *Current cancer drug targets*, 14(8), pp. 737–751.
<https://doi.org/10.2174/1568009614666141020100337>

- Martin, S., Ondrei, F., Milos, P., Frantisek, B., Petr, M., et al. (2014). Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib. *Anticancer Research*, 34, pp. 7461-7466.
<https://www.muni.cz/vyzkum/publikace/1218637>
- Meaghan, O., Amanda, N.K., Marisa, C., Vicki, L.E., Nithya, R. (2014). Effects of Cigarette Smoking on Metabolism and Effectiveness of Systemic Therapy for Lung Cancer. *J Thorac Oncol*, 9, pp. 917–926.
<https://www.sciencedirect.com/science/article/pii/S1556086415303245>
- Migliore, C., Petrelli, A., Ghiso, E., Corso, S., Capparuccia, L., Eramo, A., et al. (2008). MicroRNAs impair MET-mediated invasive growth. *Cancer research*, 68(24), pp. 10128-10136. <https://doi.org/10.1158/0008-5472.CAN-08-2148>
- Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., et al. (2008). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27 Kip1. *J. Biol. Chem*, 283, pp. 29897–29903.
<https://pubmed.ncbi.nlm.nih.gov/18708351/>
- Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., et al. (2008). Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. *Journal of Clinical Oncology*, 26(9), pp. 1472- 1478.
<https://doi.org/10.1200/JCO.2007.13.0062>
- Mitchell, H., Rosne., Alan , CD. (2014). Electrolyte disorders associated with cancer. *Advanced in Chronic Kidney Disease ACKD*, 21, pp. 7-17.
[https://ackdjournal.org/articles/S1548-5595\(13\)000](https://ackdjournal.org/articles/S1548-5595(13)000).
- Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., et al. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. *New England Journal of Medicine*, 361(10), pp. 947-957.
<https://doi.org/10.1056/NEJMoa0810699>
- Mohammad, S., Stanley, N., Cardiac Potassium Channel Disorder, an issue of cardiac electrophysiology. Clinic review articles cardiac electrophysiology clinics, [online] 5(1), pp.300-301. Available at:
<https://books.google.co.id/books?id=yUpgDAAQBAJ> [Accessed 06 April 2019]
- Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., & Allgayer, H. (2011). Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. *Oncogene*, 30(25), pp. 2888–2899. <https://doi.org/10.1038/onc.2011.13>
- Muth, M., Theophile, K., Hussein, K., Jacobi, C., Kreipe, H., & Bock, O. (2010). “Hypoxia-induced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) mRNA - a mechanism involved in SERPINE1 (PAI-1) overexpression.” *Journal of Translational Medicine*, 8(1), p.33. <https://doi.org/10.1186/1479-5876-8-33>

- Muley, T., Dienemann, H., Ebert, W. (2003 Sep-Oct). Increased CYFRA 21-1 and CEA Levels are Negative predictors of outcome in p-stage I NSCLC. *PubMed*, 23(5b), pp. 4085-93. <https://pubmed.ncbi.nlm.nih.gov/14666606/>
- Nana-Sinkam, S. P., & Geraci, M. W. (2006). MicroRNA in lung cancer. *Journal of Thoracic Oncology*, 1(9), pp. 929-931. [https://doi.org/10.1016/S1556-0864\(15\)31623-3](https://doi.org/10.1016/S1556-0864(15)31623-3)
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer version I 2015. [ebook] Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Accessed 23 Aug. 2018]
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer version I 2017 [ebook]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Accessed 23 Aug. 2018]
- Nicholson, R. I., & Johnston, S. R. (2005). Endocrine therapy—current benefits and limitations. *Breast cancer research and treatment*, 93(S1), pp. 3-10. <https://doi.org/10.1007/s10549-005-9036-4>
- Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., et al. (2005). Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. *Endocrine-related cancer*, 12(4), pp. 721-747. <https://doi.org/10.1677/erc.1.00857>
- Office of the Surgeon General (US); Office on Smoking and Health (US). (2004) The Health Consequences of Smoking: A Report of the Surgeon General. [ebook] Atlanta (GA): Centers for Disease Control and Prevention (US). ISBN-10: 0-16-051576-2. Available at: https://www.ncbi.nlm.nih.gov/books/NBK44695/pdf/Bookshelf_NBK44695.pdf [Accessed 23 Aug. 2018]
- Office on Smoking and Health (US). (2006). The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. [ebook] Atlanta (GA): Centers for Disease Control and Prevention (US). A Vision for the Future. Available from: https://www.ncbi.nlm.nih.gov/books/NBK44324/pdf/Bookshelf_NBK44324.pdf [Accessed 23 Aug. 2018]
- Onitsuka, T., Uramoto, H., Ono, K., Takenoyama, M., Hanagiri, T., Oyama, T., et al. (2010). Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. *Journal of Thoracic Oncology*, 5(5), pp. 591-596. <https://doi.org/10.1097/JTO.0b013e3181d0a4db>
- Organ, S. L., & Tsao, M.-S. (2011). An overview of the c-MET signaling pathway. *Therapeutic Advances in Medical Oncology*, 3(1_suppl), pp. S7–S19. <https://doi.org/10.1177/1758834011422556>

- Pak, M. G., Lee, C.-H., Lee, W.-J., Shin, D.-H., & Roh, M.-S. (2015). Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status. *Diagnostic Pathology*, 10(1), p. 99. <https://doi.org/10.1186/s13000-015-0339-4>
- Perhimpunan Dokter Paru Indonesia. (2003). Kanker Paru: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. [ebook] Available from: <http://www.klikpdpi.com/konsensus/konsensus-kankerparu/kankerparu.pdf> [Accessed 23 Aug. 2018]
- Pirker, R., Wiesenberger, K., Pohl, G., Minar, W. (2003), Anemia in lung cancer: clinical impact and management. *Clin Lung Cancer*, 5(2), pp. 90-7. <https://www.ncbi.nlm.nih.gov/pubmed/14596691>
- Pusat Data Kanker Nasional. (2010). *Jakarta Population-Based Cancer Registry (2005-2007)*. Jakarta: Rumah Sakit Kanker “Dharmas”.
- Ramadhaniah, F., Rahayu, P. S., & Suzanna, E. (2015). Berbagai gambaran klinis pada kanker paru di Rumah Sakit Kanker Dharmas (RSKD). *Jurnal Respirologi Indonesia*, [pdf] 35(4), pp. 203-210. Available at: https://arsip.jurnalrespirologi.org/wp-content/uploads/2016/05/JRI_2015_35_4_203-10.pdf [Accessed 23 Aug. 2018]
- Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., et al. (2011). MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. *Oncogene*, 30(9), pp. 1082–1097. <https://doi.org/10.1038/onc.2010.487>
- Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, et al. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. *Molecular cell*, 26(5), pp. 731-743. <https://doi.org/10.1016/j.molcel.2007.05.017>
- Reck, M., Heigener, D.F., Mok, T., Soria, J.C., & Rabe, K.F. (2013). Management of non-small-cell lung cancer: recent developments. *The Lancet*, 382(9893), pp. 709-719. [https://doi.org/10.1016/S0140-6736\(13\)61502-0](https://doi.org/10.1016/S0140-6736(13)61502-0)
- Richard, S.H., Julian, P. (2004). The search for low-penetrance cancer susceptibility alleles. *Oncogene*, 23, pp. 6471–6476. <https://www.nature.com/articles/1207951>
- Riely, G. J., Pao, W., Pham, D., Li, A. R., Rizvi, N., Venkatraman, E. S., et al. (2006). Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clinical cancer research*, 12(3), pp. 839-844. <https://doi.org/10.1158/1078-0432.CCR-05-1846>
- Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014). The p53/miR-34 axis in development and disease. *Journal of molecular cell biology*, 6(3), pp. 214-230. <https://doi.org/10.1093/jmcb/mju003>

- Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *The Lancet Oncology*, 13(3), pp. 239-246. [https://doi.org/10.1016/S1470-2045\(11\)70393-X](https://doi.org/10.1016/S1470-2045(11)70393-X)
- Ruby, J. G., Jan, C., Player, C., Axtell, M. J., Lee, W., Nusbaum, C., et al. (2006). Large-scale sequencing reveals 21U-RNAs and additional microRNAs and endogenous siRNAs in *C. elegans*. *Cell*, 127(6), pp. 1193-1207. <https://doi.org/10.1016/j.cell.2006.10.040>
- Ryo, Y., Mitsuo, S., Tomohiko, K., Tetsunari, H., Naoyuki, Y., et al. (2015). Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. *Cancer Med*, 4(4), pp. 551-564. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402070>.
- Sattler, M., Reddy, M. M., Hasina, R., Gangadhar, T., & Salgia, R. (2011). The role of the c-Met pathway in lung cancer and the potential for targeted therapy. *Therapeutic Advances in Medical Oncology*, 3(4), pp.171–184. <https://doi.org/10.1177/1758834011408636>
- Secretan, B., Straif, K., Baan, R., Grosse, Y., El Ghissassi, F., Bouvard, V., et al. (2009). A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. *The lancet oncology*, 10(11), pp. 1033-1034. <https://pubmed.ncbi.nlm.nih.gov/19891056/>
- Sequist, L. V., Joshi, V. A., Jänne, P. A., Muzikansky, A., Fidias, P., Meyerson, M., et al. (2007). Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. *The oncologist*, 12(1), pp. 90-98. <https://doi.org/10.1634/theoncologist.12-1-90>
- Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Janne, P. A., et al. (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. *Journal of clinical oncology*, 26(15), pp. 2442-2449. <https://doi.org/10.1200/JCO.2007.14.8494>
- Sequist, L. V., Von Pawel, J., Garmey, E. G., Akerley, W. L., Brugger, W., Ferrari, D., et al. (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. *Journal of Clinical Oncology*, 29(24), pp. 3307-3315. <https://doi.org/10.1200/JCO.2010.34.0570>
- Sequist, L. V., Yang, J. C. H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., et al. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *Journal of clinical oncology*, 31(27), pp. 3327-3334. <https://doi.org/10.1200/JCO.2012.44.2806>

- Seymour, G. (2001). Metabolic Susceptibility Genes As Cancer Risk Factors: Time for a Reassessment? *Cancer Epidemiology, Biomarkers & Prevention*, 10, pp. 1233–1237. <https://cebp.aacrjournals.org/content/10/12/1233>
- Shah, M. Y., Calin, G.A. (2011). MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. *Genome Med*, 3, p.56. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238182/>
- Sharma, S. V., Bell, D. W., Settleman, J., and Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. *Nat. Rev. Cancer*, 7, pp. 169–181. <https://pubmed.ncbi.nlm.nih.gov/17318210/>
- Sibilia, M., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., and Holcman, M. (2007). The epidermal growth factor receptor: from development to tumorigenesis. *Differentiation*, 75, pp. 770–787. <https://pubmed.ncbi.nlm.nih.gov/17999740>
- Siegelin, M. D., Borczuk, A. C. (2014). Epidermal growth factor receptor mutations in lung adenocarcinoma. *Laboratory investigation*, 94(2), pp.129-137. <https://doi.org/10.1038/labinvest.2013.147>
- Sisko, A., Hannu, R., Jukka, H. (2011) Cytochrome P450–Mediated Pulmonary Metabolism of Carcinogens Regulation and Cross-Talk in Lung Carcinogenesis. *Am J Respir Cell Mol Biol*, 44, pp. 583–590. <https://doi.org/10.1165/rcmb.2010-0189RT>
- Stefan, H., Birgit, W., Karina, H., Kirsten, S., Steffen, U., Farshid, D. (2017). Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis. *British Journal of Cancer*, 116, pp.1037–1045. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396105/>
- Stinson, S., Lackner, M. R., Adai, A. T., Yu, N., Kim, H. J., O'Brien, C., et al. (2011). TRPS1 targeting by miR-221/222 promotes the epithelial to mesenchymal transition in breast cancer. *Sci. Signal*, 4, pp.ra41. <https://pubmed.ncbi.nlm.nih.gov/21673316>
- Subramanian, J., & Govindan, R. (2007). Lung cancer in never smokers: a review. *Journal of clinical oncology*, 25(5), pp.561-570. <https://doi.org/10.1200/JCO.2006.06.8015>
- Sun, Q., Jiang, CW., Tan, ZH., Hou, LY., Dong, H., Liu, K., et al. (2017). Mir 222 promotes proliferation, migration and invasion of lung adenocarcinoma cells by targeting ETS1. *European Review for Medical and Pharmacological Sciences*, 21, pp. 2385-2391. <https://www.europeanreview.org/wp/wp-content>
- Surveillance, Epidemiology, and End Results Program. (2018). *Lung and Bronchus Cancer - Cancer Stat Facts*. [online] Seer.cancer.gov. Available at: <https://seer.cancer.gov/statfacts/html/lungb.html> [Accessed 23 Aug. 2018].

- Suzanna, E., Sirait, T., Rahayu, P., Shalmont, G., Anwar, E., Andalusia, R., *et al.* (2012). Hospital-based cancer registry in Dharmas Hospital - National Cancer Center, 1993-2007. *Indonesian Journal of Cancer*, 6(4), pp. 181-205.
- Tania, F., Sara, D., Giovanni, B. (2015). Oncogenic MicroRNAs: Key Players in Malignant Transformation. *Cancers*, 7, pp. 2466–2485.
<https://www.mdpi.com/2072-6694/7/4/904/pdf>
- Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., *et al.* (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. *Cell cycle*, 6(13), pp. 1586-1593.
<https://doi.org/10.4161/cc.6.13.4436>
- Taylor, R., Najafi, F., Dobson, A. (2007). Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. *International journal of epidemiology*, 36(5), pp. 1048-1059.
<https://doi.org/10.1093/ije/dym158>
- Tim, E., Athena, M., Richard, H. (2008). Identification of low penetrance alleles for lung cancer: The GENetic Lung Cancer Predisposition Study (GELCAPS). *BMC Cancer*, 8, pp. 244.
<https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-8-244>
- Tomita, M., Shimizu, T., Hara, M., Ayabe, T., Onitsuka, T. (2009). Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. *Anticancer Res*, 29(7), pp. 2687-90.
<http://www.ncbi.nlm.nih.gov/pubmed/19596947>
- Torre, L.A., Siegel, R.L., Jemal, A. (2016). Lung Cancer Statistics. *Lung Cancer and Personalized Medicine*, pp. 1–19. https://doi.org/10.1007/978-3-319-24223-1_1
- Tsao, M. S., Sakurada, A., Cutz, J. C., Zhu, C. Q., Kamel-Reid, S., Squire, J., *et al.* (2005). Erlotinib in lung cancer—molecular and clinical predictors of outcome. *New England Journal of Medicine*, 353(2), pp. 133-144.
<https://doi.org/10.1056/NEJMoa050736>
- Uchikov, A., Dimitrov, I., Terzieva, D., Mateva, N., Kuznanova, D., Bataski, A. (2008). Diagnostic value of the serum tumor markers CEA and Cyfra 21-1 patients with non-small cell lung cancer. *PubMed*, 3, pp. 18-20.
<https://www.ncbi.nlm.nih.gov/pubmed/20058724>
- Vicentini, C., Festuccia, C., Gravina, G. L., Angelucci, A., Marronaro, A., and Bologna, M. (2003). Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 *in vitro* on human cell lines and primary cultures. *J. Cancer Res. Clin. Oncol.* 129, pp. 165–174. <https://www.ncbi.nlm.nih.gov/pubmed/12712332>

- Wald, N. J., Nanchahal, K., Thompson, S. G., & Cuckle, H. S. (1986). Does breathing other people's tobacco smoke cause lung cancer? *British Medical Journal (Clinical Research Ed.)*, 293(6556), pp. 1217–1222. <https://doi.org/10.1136/bmj.293.6556.1217>
- Wang, W. S., Chen, P. M., Chiou, T. J., Liu, J. H., Lin, J. K., Lin, T. C., et al. (2007). Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. *Clin. Cancer Res*, 13, pp. 3597–3604.
- Wang, X., Han, H., Duan, q., Khan, U, Hu, Y., Yao, X. (2014), Changes of serum albumin level and systemic inflammatory respons in inoperable nan-small cell lung cancer patients after chemotherapy. *J Cancer Res Ther*, 10(4), pp. 1019-23. <https://www.ncbi.nlm.nih.gov/pubmed/25579547>.
- Watanabe K, Emoto N, Hamano E, et al. (2012). Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. *Int J Cancer*, 2012 in press. 2011 Jun 23.
- Webster, R. J., Giles, K. M., Price, K. J., Zhang, P. M., Mattick, J. S., and Leedman, P. J. (2009). Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. *J. Biol. Chem*, 284, pp. 5731–5741. <https://www.ncbi.nlm.nih.gov/pubmed/19073608>
- Wiemer, E. a C. (2007) The role if micro-RNAs in cancer: No small matter. *Eur. J. Cancer*, 43, pp. 1529-1544. <http://dipbsf.uninsubria.it/monti/BFPN%202009/miRNA-G.pdf>
- Yiming, X., Chongjun, Z., Shengguang, D., Haitao, H., Zheriya, S. (2015). MicroRNA-221 promotes human nan-small cell lung cancer cell H460 growth. *Int J Clin Exp Med*, 9(2), pp. 2024-2030. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402779>.
- Ying, J., Li, Z., Fang, P. (2013). Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer. *Clinics (Sao Paulo)*, 68(5), pp. 686-693. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654299/>.
- Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003). PUMA mediates the apoptotic response to p53 in colorectal cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, 100(4), pp. 1931–1936. <https://doi.org/10.1073/pnas.2627984100>
- Zhang, C. -Z., Zhang, J. -X., Zhang, A. -L., Shi, Z. -D., Han, L., Jia, Z. -F., et al. (2010). MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. *Molecular Cancer*, 9(1), p. 229. <https://doi.org/10.1186/1476-4598-9-229>
- Zhao, J-J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., et al. (2008). MicroRNA-221/222 Negatively Regulates Estrogen Receptor α and Is Associated with Tamoxifen Resistance in Breast Cancer. *Journal of Biological Chemistry*, 283(45), pp. 31079-31086. <https://doi.org/10.1074/jbc.M806041200>

Zong, W. -X., Lindsten, T., Ross, A.J., MacGregor, G.R., & Thompson, C.B.
(2001). BH3-only proteins that bind pro-survival Bcl-2 family members fail
to induce apoptosis in the absence of Bax and Bak. *Genes & Development*,
15(12), pp. 1481–1486. <http://doi.org/10.1101/gad.897601>